vs
Apellis Pharmaceuticals, Inc.（APLS）与National Storage Affiliates Trust（NSA）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是National Storage Affiliates Trust的1.1倍（$199.9M vs $187.0M），National Storage Affiliates Trust净利率更高（12.2% vs -29.5%，领先41.7%），National Storage Affiliates Trust同比增速更快（-1.6% vs -5.9%），National Storage Affiliates Trust自由现金流更多（$299.8M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -2.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
National Storage Affiliates Trust是一家总部位于美国的房地产投资信托，专注于自助仓储资产，在美国数十个州持有、运营及收购自助仓储设施，为居民和商业客户提供安全的存储服务。
APLS vs NSA — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $187.0M |
| 净利润 | $-59.0M | $22.9M |
| 毛利率 | — | 72.5% |
| 营业利润率 | -25.6% | 20.2% |
| 净利率 | -29.5% | 12.2% |
| 营收同比 | -5.9% | -1.6% |
| 净利润同比 | -62.2% | 36.8% |
| 每股收益（稀释后） | $-0.40 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $187.0M | ||
| Q3 25 | $458.6M | $188.7M | ||
| Q2 25 | $178.5M | $188.8M | ||
| Q1 25 | $166.8M | $188.4M | ||
| Q4 24 | $212.5M | $190.1M | ||
| Q3 24 | $196.8M | $193.6M | ||
| Q2 24 | $199.7M | $190.4M | ||
| Q1 24 | $172.3M | $196.1M |
| Q4 25 | $-59.0M | $22.9M | ||
| Q3 25 | $215.7M | $18.4M | ||
| Q2 25 | $-42.2M | $19.5M | ||
| Q1 25 | $-92.2M | $13.0M | ||
| Q4 24 | $-36.4M | $16.7M | ||
| Q3 24 | $-57.4M | $18.7M | ||
| Q2 24 | $-37.7M | $17.1M | ||
| Q1 24 | $-66.4M | $59.0M |
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 70.7% | ||
| Q2 25 | — | 70.5% | ||
| Q1 25 | — | 70.7% | ||
| Q4 24 | — | 72.5% | ||
| Q3 24 | — | 72.8% | ||
| Q2 24 | — | 72.6% | ||
| Q1 24 | — | 72.1% |
| Q4 25 | -25.6% | 20.2% | ||
| Q3 25 | 48.7% | 15.8% | ||
| Q2 25 | -18.6% | 16.5% | ||
| Q1 25 | -50.0% | 11.0% | ||
| Q4 24 | -12.3% | 14.5% | ||
| Q3 24 | -24.0% | 15.8% | ||
| Q2 24 | -14.7% | 17.2% | ||
| Q1 24 | -36.0% | 48.9% |
| Q4 25 | -29.5% | 12.2% | ||
| Q3 25 | 47.0% | 9.8% | ||
| Q2 25 | -23.6% | 10.3% | ||
| Q1 25 | -55.3% | 6.9% | ||
| Q4 24 | -17.1% | 8.8% | ||
| Q3 24 | -29.2% | 9.7% | ||
| Q2 24 | -18.9% | 9.0% | ||
| Q1 24 | -38.5% | 30.1% |
| Q4 25 | $-0.40 | $0.23 | ||
| Q3 25 | $1.67 | $0.17 | ||
| Q2 25 | $-0.33 | $0.19 | ||
| Q1 25 | $-0.74 | $0.10 | ||
| Q4 24 | $-0.30 | $0.19 | ||
| Q3 24 | $-0.46 | $0.18 | ||
| Q2 24 | $-0.30 | $0.16 | ||
| Q1 24 | $-0.54 | $0.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $23.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $946.0M |
| 总资产 | $1.1B | $5.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $23.3M | ||
| Q3 25 | $479.2M | $26.3M | ||
| Q2 25 | $370.0M | $26.1M | ||
| Q1 25 | $358.4M | $19.3M | ||
| Q4 24 | $411.3M | $50.4M | ||
| Q3 24 | $396.9M | $69.9M | ||
| Q2 24 | $360.1M | $59.0M | ||
| Q1 24 | $325.9M | $64.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $946.0M | ||
| Q3 25 | $401.2M | $973.1M | ||
| Q2 25 | $156.3M | $1.0B | ||
| Q1 25 | $164.2M | $1.0B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $986.9M | ||
| Q2 24 | $264.3M | $1.2B | ||
| Q1 24 | $266.7M | $1.3B |
| Q4 25 | $1.1B | $5.1B | ||
| Q3 25 | $1.1B | $5.1B | ||
| Q2 25 | $821.4M | $5.2B | ||
| Q1 25 | $807.3M | $5.3B | ||
| Q4 24 | $885.1M | $5.4B | ||
| Q3 24 | $901.9M | $5.4B | ||
| Q2 24 | $904.5M | $5.3B | ||
| Q1 24 | $831.9M | $5.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $338.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $299.8M |
| 自由现金流率自由现金流/营收 | -7.1% | 160.3% |
| 资本支出强度资本支出/营收 | 0.1% | 20.7% |
| 现金转化率经营现金流/净利润 | — | 14.79× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $541.5M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $338.5M | ||
| Q3 25 | $108.5M | $100.2M | ||
| Q2 25 | $4.4M | $79.9M | ||
| Q1 25 | $-53.4M | $85.6M | ||
| Q4 24 | $19.4M | $363.1M | ||
| Q3 24 | $34.1M | $105.7M | ||
| Q2 24 | $-8.3M | $83.2M | ||
| Q1 24 | $-133.0M | $94.0M |
| Q4 25 | $-14.3M | $299.8M | ||
| Q3 25 | $108.3M | $88.0M | ||
| Q2 25 | $4.4M | $73.8M | ||
| Q1 25 | $-53.4M | $79.9M | ||
| Q4 24 | $19.3M | $344.4M | ||
| Q3 24 | — | $101.8M | ||
| Q2 24 | $-8.4M | $79.5M | ||
| Q1 24 | $-133.3M | $88.6M |
| Q4 25 | -7.1% | 160.3% | ||
| Q3 25 | 23.6% | 46.6% | ||
| Q2 25 | 2.5% | 39.1% | ||
| Q1 25 | -32.0% | 42.4% | ||
| Q4 24 | 9.1% | 181.2% | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | -4.2% | 41.7% | ||
| Q1 24 | -77.3% | 45.2% |
| Q4 25 | 0.1% | 20.7% | ||
| Q3 25 | 0.0% | 6.5% | ||
| Q2 25 | 0.0% | 3.2% | ||
| Q1 25 | 0.0% | 3.0% | ||
| Q4 24 | 0.0% | 9.8% | ||
| Q3 24 | 0.0% | 2.0% | ||
| Q2 24 | 0.0% | 1.9% | ||
| Q1 24 | 0.2% | 2.7% |
| Q4 25 | — | 14.79× | ||
| Q3 25 | 0.50× | 5.44× | ||
| Q2 25 | — | 4.10× | ||
| Q1 25 | — | 6.59× | ||
| Q4 24 | — | 21.70× | ||
| Q3 24 | — | 5.65× | ||
| Q2 24 | — | 4.88× | ||
| Q1 24 | — | 1.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NSA
暂无分部数据
